Table 3.
Disease activity at diagnosis and 1-year follow up stratified by LAMP-2-ANCA seropositivity.
| PSV Total | Small Vessel | Medium Vessel | Large Vessel | |||||
|---|---|---|---|---|---|---|---|---|
| a LAMP-2-ANCA | − | + | − | + | − | + | − | + |
| Disease activity (total pVAS), median (range) | ||||||||
| b at diagnosis | 19 (5–50) | * 15 (1–36) | 20 (7–50) | 18 (6–36) | 8 (5–31) | 7 (1–18) | 19 (6–20) | 15 (6–26) |
| c at 1-year | 0 (0–4) | 0 (0–12) | 0 (0–6) | 0 (0–12) | 0 (0) | 1 (0–4) | 2 (3–4) | 0 (0–12) |
| d Inactive disease (total pVAS ≤ 1), n (%) | ||||||||
| at 1-year | 26 (37.1) | 25 (35.7) | 19 (48.7) | 12 (30.8) | 5 (38.5) | 4 (30.8) | 2 (11.1) | 9 (50.0) |
a LAMP-2-ANCA-seronegative indicated by (−) and seropositive indicated by (+). b At diagnosis, pVAS available for n = 90 PSV patients. * Significant difference in disease activity (p = 0.0176) across all groups based on unpaired t-test. c At 1 year post-diagnosis, pVAS available for n = 70 PSV patients: n = 39 SVV (15 LAMP2 ANCA+), n = 13 MVV (8 LAMP2 ANCA+), n = 18 LVV (13 LAMP2 ANCA+). d Inactive disease defined as total pVAS ≤ 1 at one-year post-diagnosis. Percentage is relative to the total number of seronegative or seropositive participants of the same vessel size.